Anti-HIV-1 gp120 Recombinant Antibody (C108G) (CAT#: MRO-116LC)

This product is a recombinant chimpanzee anti-HIV-1 monoclonal antibody. C108G specifically binds to gp120 and can be potentially used in the treatment of acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Datasheet
  • MSDS
  • COA
ELISA

Figure 1 Effects of reduction and deglycosylation on stability of epitopes in the V2 and other domains.

Figure 1 Effects of reduction and deglycosylation on stability of epitopes in the V2 and other domains.

Recombinant BaL gp120 was captured on wells of a 96-well ELISA plate either untreated (open squares) or after deglycosylation with peptide N-glycosidase F (PNGase F; closed diamonds) or reduction by DTT (closed triangles). The reactivity of the indicated MAbs to control or treated rgp120 was titrated for 1 h at 37°C and bound antibody detected with alkaline phosphatase-conjugated anti-IgG, followed by incubation with alkaline phosphatase substrate. OD405, optical density at 405 nm.

The C108g Epitope in the V2 Domain of gp120 Functions as a Potent Neutralization Target When Introduced into Envelope Proteins Derived from Human Immunodeficiency Virus Type 1 Primary Isolates

Neut

Figure 2 Effects of mutations in the JR-FL V2 domain on neutralization by V2-specific MAbs C108g and 10/76b and MAbs to the V3 region (4117C) and CD4-binding domain (5145A).

Figure 2 Effects of mutations in the JR-FL V2 domain on neutralization by V2-specific MAbs C108g and 10/76b and MAbs to the V3 region (4117C) and CD4-binding domain (5145A).

Neutralization assays were performed with env deleted, luc-expressing NL4-3 provirus pseudotypes with either the parental JR-FL Env (closed triangles) or the JR(GKV) variant expressing the C108g epitope in the JR-FL background (open triangles).

The C108g Epitope in the V2 Domain of gp120 Functions as a Potent Neutralization Target When Introduced into Envelope Proteins Derived from Human Immunodeficiency Virus Type 1 Primary Isolates

Neut

Figure 3 Analysis of neutralizing activities of MAbs against various domains for the viruses pseudotyped with the two parental Envs SF162 (closed circles) and JR-FL (closed triangles) and with the two C108g-expressing variants SF(NI GKV) (open circles) and JR(GKV) (open triangles).

Figure 3 Analysis of neutralizing activities of MAbs against various domains for the viruses pseudotyped with the two parental Envs SF162 (closed circles) and JR-FL (closed triangles) and with the two C108g-expressing variants SF(NI GKV) (open circles) and JR(GKV) (open triangles).

The MAb used and the domain it recognizes are indicated at the top of each panel.

The C108g Epitope in the V2 Domain of gp120 Functions as a Potent Neutralization Target When Introduced into Envelope Proteins Derived from Human Immunodeficiency Virus Type 1 Primary Isolates

Inhib

Figure 4 Fluorescence-activated cell sorter assays of the inhibition of binding of either gp120 to U87 cells expressing CD4 by MAbs or sCD4.

Figure 4 Fluorescence-activated cell sorter assays of the inhibition of binding of either gp120 to U87 cells expressing CD4 by MAbs or sCD4.

Env proteins were used at 1.0 g/ml, MAbs at 20 g/ml, and sCD4 at 100 g/ml. Binding of Env proteins to cells was detected by subsequent staining with biotinylated HIVIG, followed by R-phycoerythrin-conjugated streptavidin and quantitated on a Becton-Dickinson FACScalibur flow cytometer. The MAb used and the extent of inhibition compared to the control in the absence of antibody, measured as the decrease in mean fluorescence intensity compared to the control, are indicated in each panel.

The C108g Epitope in the V2 Domain of gp120 Functions as a Potent Neutralization Target When Introduced into Envelope Proteins Derived from Human Immunodeficiency Virus Type 1 Primary Isolates


Specifications

  • Host Species
  • Chimpanzee
  • Type
  • Chimpanzee antibody
  • Specificity
  • HIV-1
  • Clone
  • C108G
  • Applications
  • ELISA, Neut, Inhib
  • Related Disease
  • AIDS

Applications

  • Application Notes
  • The HIV-1 gp120 antibody has been reported in applications of Enzyme-linked Immunosorbent Assay, Neutralization, Inhibition.

Target

  • Alternative Names
  • Human immunodeficiency virus type 1; HIV-1; Envelope glycoprotein GP120; gp120; HIV envelope

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Clone C108G"

See other products for "HIV-1 gp120"

Single-domain Antibody

Chimeric Antibody

CAT Product Name Application Type
MRO-135LC Anti-HIV-1 gp120 Recombinant Antibody (CAG1-51-4) ELISA, WB, Neut Chimeric antibody (mouse/human)
MRO-135LC-S(P) Anti-HIV-1 gp120 Recombinant Antibody scFv Fragment (CAG1-51-4) ELISA, WB Chimeric antibody (mouse/human)
MRO-135LC-F(E) Anti-HIV-1 gp120 Recombinant Antibody Fab Fragment (CAG1-51-4) ELISA, WB Chimeric antibody (mouse/human)

Rabbit Monoclonal Antibody

CAT Product Name Application Type
MOR-4220 Rabbit Anti-HIV-1 gp120 Recombinant Antibody (clone SI299DS) WB, ELISA Rabbit IgG

Humanized Antibody

CAT Product Name Application Type
PABX-101-S(P) Human Anti-HIV-1 gp120 Recombinant Antibody (clone PG9); scFv Fragment WB, ELISA, FuncS Human scFv

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for MRO-116LC. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare